Merck & Co., Inc. (NYSE: MRK) is a Healthcare company (Drug Manufacturers - General) with a market capitalization of $356.1B. The Maz Rating grades it against the other companies in its sector.
Merck & Co., Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $144.46, Merck & Co., Inc. trades at 145.9x trailing earnings, 5.3x sales and 8.0x book value, with an EV/EBITDA of 33.9. Over the last twelve months it generated about $67.3B of revenue and $2.4B of net income. It runs a gross margin of 74.7%, an operating margin of 13.6% and a net margin of 3.6%. It shows return on equity of 5.3%, return on invested capital of 4.4% and a free cash flow yield of 4.1%. On the balance sheet: a debt-to-equity ratio of 1.20 and a current ratio of 1.35. Over the past 52 weeks the share price ranged from $92.11 to $156.92, with a beta of 0.22.
Merck & Co., Inc. pays a dividend yielding 2.35%, with 341% of earnings paid out. Its Maz Dividend Score is 2.30 out of 5, ranked against the other dividend payers in its sector (Safety 1.30, Growth 2.77, Yield 3.77, Consistency 4.63).
38 Wall Street analyst ratings cover the stock: 26 Buy, 11 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Merck & Co., Inc. (MRK) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 14.8% / 30% · (Cash+Inv) / Mkt Cap (36m) 3.10% / 30% · Interest income / Revenue 0.29% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 14.8% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 2.66% / 33% · Receivables / Mkt Cap (36m) 3.51% / 49% · Interest income / Revenue 0.29% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 14.8% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 2.66% / 33.33% · Receivables / Mkt Cap (24m) 3.51% / 33.33% · Interest income / Revenue 0.29% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 39.1% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 7.02% / 33.33% · Receivables / Avg Assets (4Q) 9.50% / 33.33% · Interest income / Revenue 0.29% / 5% | Fail |
| FTSE | Debt / Total Assets 40.5% / 33.33% · (Cash+ST Inv) / Total Assets 7.27% / 33.33% · (Cash+Recv) / Total Assets 16.9% / 33.33% · Interest income / Revenue 0.29% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Merck & Co., Inc. (MRK) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. Merck & Co., Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 0.29% of each dividend: Merck & Co., Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.